- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00270075
A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery
17. mai 2011 oppdatert av: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Orthopedic or Cardiovascular Surgery, to Facilitate Presurgical Autologous Blood Donation (A Double-blind, Randomized, Dose Finding Study)
The purpose of this study is to determine whether epoetin alfa will enable self-donation of at least 4 units of blood during the 2-week period before surgery (which is a shorter period of time than the conventional 3-week blood donation period before surgery) in patients who are not anemic and who will be undergoing orthopedic or heart and blood vessel surgery.
Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Patients undergoing orthopedic or heart and blood vessel surgery frequently require blood transfusions both during and after the operation.
Patients often have their own blood collected for this purpose over a standard 3- to 4-week period before surgery.
A large percentage of patients are not able to pre-deposit their own blood for transfusion.
For such patients, an agent that can facilitate self-donation and reduce the need for transfusions from others in less time than the conventional 3 weeks before surgery may improve the overall safety of surgery.
This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate whether epoetin alfa will enable the self-deposit of at least 4 units of blood in the abbreviated presurgical time period of 2 weeks by patients who are not anemic and who are undergoing orthopedic or heart and blood vessel surgery.
The study consists of a 7-day screening period when patients will be tested for eligibility for the study, a 14-day treatment and blood collection period, and a follow-up evaluation period beginning 1 day before surgery and continuing to a study termination visit performed at the patient's discharge from the hospital after surgery.
Eligible patients will be randomly assigned to one of four treatment groups: epoetin alfa 300 units/kilogram (U/kg), epoetin alfa 600 U/kg, placebo to match the volume of epoetin alfa 300 U/kg, or placebo to match the volume of epoetin alfa 600 U/kg, given by injection into a vein.
Twice as many patients will receive treatment with epoetin alfa as will receive treatment with placebo.
A total of 3 doses of study medication will be administered to each patient, one dose given on each of Days 1, 4, and 7 of the study.
Additionally, from Day 1 to Day 14 of the study, all patients will receive 200 milligrams of iron and 5 milligrams of a folate supplement daily by mouth to support red blood cell generation.
On Day 1, before the first dose of study drug, one unit of blood will be collected from each patient and stored for self-donated blood transfusion.
An additional unit of blood will be collected from each patient (before administration of study drug) and stored for self-donated blood transfusion on each of Days 4, 7, 11, and 14, only if the patient's hemoglobin level is >11.0 g/dL; if a patient's hemoglobin level is <=11.0
g/dL on any of these days, no blood will be collected on that day, although study drug will be given.
A maximum of 5 units of blood will be collected from any patient.
If sufficient units for the planned surgery are not collected, preparations will be made for patients to receive needed units of blood from donors.
The study duration is 14 days, ending before surgery.
Safety evaluations will include laboratory tests, vital signs, and reporting of the incidence of adverse events.
Effectiveness will be evaluated by comparing the number of self-donated units of blood collected within 2 weeks, and the change in hemoglobin level among the different treatment groups from before the start of the study to the end of the study.
The study hypothesis is that in an abbreviated (2-week) period before surgery, epoetin alfa will facilitate collection of at least 4 units of self-donated blood in patients who are not anemic and who are undergoing orthopedic or heart and blood vessel surgery.
Epoetin alfa 300 units/kilogram (U/kg), epoetin alfa 600 U/kg, placebo matching the volume of the 300 U/kg dose, or placebo matching the volume of the 300 U/kg dose, by injection into a vein; given on each of Days 1, 4, and 7 of the study.
Studietype
Intervensjonell
Registrering (Faktiske)
80
Fase
- Fase 2
- Fase 3
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients scheduled for orthopedic or heart and blood vessel surgery
- requirement of 3 or more units of blood
- who are non-anemic (hemoglobin within normal range of 12.0 - 18.0 grams/deciliter)
- having laboratory tests within normal ranges
Exclusion Criteria:
- Patients with history of any primary blood disease
- having signs and symptoms of significant disease/dysfunction, such as signs and symptoms of significant heart and blood vessel disease (in patients undergoing orthopedic surgery) or severe alteration in rhythm of the heartbeat, persistent brief attacks of chest pain, or significant heart failure in which the heart is unable to maintain adequate circulation of blood (in patients undergoing heart and blood vessel surgery)
- having uncontrolled high blood pressure or signs and symptoms of significant dizziness, faintness, or lightheadedness which appear only on standing and are caused by low blood pressure
- who have received a blood transfusion within 1 month before the start of the study
- having a body weight greater than 100 kilograms (approximately 220 pounds)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Number of self-donated units of blood collected within 2 weeks; Change in hemoglobin level from before the start of the study to the end of the study
|
Sekundære resultatmål
Resultatmål |
---|
Changes in safety parameters (laboratory tests, vital signs, physical examination, and adverse events) from before the study to the end of the study
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 1990
Studiet fullført (Faktiske)
1. mai 1992
Datoer for studieregistrering
Først innsendt
22. desember 2005
Først innsendt som oppfylte QC-kriteriene
22. desember 2005
Først lagt ut (Anslag)
26. desember 2005
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
18. mai 2011
Siste oppdatering sendt inn som oppfylte QC-kriteriene
17. mai 2011
Sist bekreftet
1. februar 2011
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR005896
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Blodoverføring
-
John M. StulakFullført
-
Assiut UniversityHar ikke rekruttert ennåGyldighet av Blood Pool SUV-ratio i identifisering av malignitet i tilfelle av syk lever
-
Academisch Medisch Centrum - Universiteit van Amsterdam...European Regional Development Fund; HaermonicsAvsluttetPostoperativ blødning | Hjertetamponade | Hjertekirurgiske prosedyrer | Retained Blood SyndromeNederland
-
Haukeland University HospitalNorwegian Armed Forces Medical ServiceFullførtTraume | Svært miljø | Blod bank | Buddy TransfusionNorge
-
Bactiguard ABKarolinska University HospitalFullførtKirurgi | Central Line Associated Blood Stream Infections (CLABSI)Sverige
-
Columbia UniversityFullførtTwin Twin Transfusion SyndromeForente stater
-
University of Southern CaliforniaAktiv, ikke rekrutterendeTwin Twin Transfusion SyndromeForente stater
-
University of South FloridaFullførtTwin Twin Transfusion SyndromeForente stater
-
Guang'anmen Hospital of China Academy of Chinese...UkjentKoronar hjertesykdom | Ustabil angina | Blood Stasis SyndromeKina
-
Medical College of WisconsinNational Heart, Lung, and Blood Institute (NHLBI); University of Wisconsin... og andre samarbeidspartnereRekrutteringPlutselig spedbarnsdød | Medfødt hjertesykdom | Graviditetstap | Gastroschisis | Fosterdød | Brugada syndrom | Høyrisikograviditet | Dødfødsel | Langt QT-syndrom | Fosterdød | Fødselsskade | Tvilling Monochorionic Monoamniotic Placenta | Twin Twin Transfusion Syndrome | Fosterhydrops | Fosterarytmi | Intrauterin fosterdød | Fetal... og andre forholdForente stater
Kliniske studier på epoetin alfa
-
Catholic University of the Sacred HeartSOFAR S.p.A.UkjentGodartet, premalignt og ondartet gynekologisk sykdom begrenset til bekkenetItalia
-
Xiangya Hospital of Central South UniversityUkjent
-
First Affiliated Hospital Xi'an Jiaotong UniversityRekruttering
-
Peking University Third HospitalRekrutteringSkjoldbrusk øyesykdomKina
-
University of EdinburghRekrutteringAortastenose | Karsinoid syndrom | Kjemoterapi-indusert systolisk dysfunksjonStorbritannia
-
SOFAR S.p.A.FullførtLivmorsykdommer | Adnexal sykdommerItalia
-
UMC UtrechtHar ikke rekruttert ennåMetastatisk tykktarmskreft | Metastatisk kreft i leveren
-
Sichuan Provincial People's HospitalRekrutteringAldosteronproduserende adenomKina
-
Institute of Liver and Biliary Sciences, IndiaFullførtAkutt leversvikt | Akutt ved kronisk leversviktIndia